Skip to main content
. 2020 Jan 10;9:1436. doi: 10.3389/fonc.2019.01436

Table 3.

Comparison of clinical and H3K27M-status in personalized and control cohort.

Personalized Control
Age in years, median (range) 6.6 (4.8–19) 8.2 (2.4–11.1)
Gender (m:f) 4:5 6:3
Localization
Pons 7 8
Thalamus 1 1
Spinal 1
H3K27M detection
H3F3A 7 4
HISTH3B 2 1
IHC 0 4
Backbone treatment (first line)
Nimotuzumab/vinorelbine 6 4
Temozolomide 3 4
Other 0 1

IHC, immunohistochemistry.